超1300只，创新高

Core Insights - Over 1300 active equity funds have reached new net asset value highs, significantly outperforming the market index and achieving excess returns [1][2] - The recent profitability of active equity funds is attributed to structural market opportunities, the active management capabilities of fund managers, and an improved policy environment [1][3] Fund Performance - As of August 13, the average net asset value growth rate for active equity funds this year is 16.03%, with 1332 funds achieving new highs, representing over 25% of all active equity funds [2] - The performance of equity mixed funds and ordinary stock funds has outpaced the CSI 300 index by over 12 percentage points, with respective increases of 19.67% and 19.83% [2] Market Dynamics - The continuous rise of the Shanghai Composite Index has driven up stock prices, closely linking the net asset values of active equity funds to the performance of their underlying stocks [2] - Fund strategies that align with current market trends have contributed to the increase in fund net values [3] Managerial Expertise - Skilled fund managers leverage their investment research capabilities and market experience to identify trends and opportunities, enhancing fund performance through strategic asset allocation and stock selection [3] Capital Inflows - Increased risk appetite and favorable market conditions have attracted significant capital inflows into equity funds, providing ample support for investment operations and driving net asset values higher [3] Future Outlook - The market is expected to enter a positive feedback loop of capital inflows and rising prices, supported by improved investor confidence and favorable valuations compared to the bond market [4] - Investment recommendations include focusing on high-growth sectors such as AI, innovative pharmaceuticals, non-ferrous metals, and military industries, as well as key themes and reform areas [4] Short-term Strategy - The market may continue to experience oscillations, with a focus on low-valuation blue-chip stocks and sectors like pharmaceuticals and technology that have seen limited prior gains [5] - Investors are advised to prioritize companies and industries with expected earnings that exceed market expectations or show signs of recovery [5]